Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

A number of other equities research analysts have also recently commented on SYRS. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.24 on Thursday. The firm’s fifty day moving average is $0.44 and its two-hundred day moving average is $2.21. The firm has a market cap of $6.39 million, a price-to-earnings ratio of -0.08 and a beta of 1.31. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period last year, the business earned ($1.35) EPS. Research analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Transactions at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the sale, the director now owns 41,070 shares of the company’s stock, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Exome Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after purchasing an additional 139,400 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after buying an additional 17,416 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals in the 3rd quarter valued at $34,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.